Revolve Wealth Partners LLC Takes $468,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Revolve Wealth Partners LLC acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 927 shares of the company’s stock, valued at approximately $468,000.

Other institutional investors also recently bought and sold shares of the company. Riverview Trust Co acquired a new position in shares of IDEXX Laboratories during the 1st quarter worth approximately $26,000. Crewe Advisors LLC purchased a new stake in shares of IDEXX Laboratories during the 1st quarter valued at approximately $26,000. Ridgewood Investments LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $27,000. Institutional & Family Asset Management LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $28,000. Finally, Strategic Investment Solutions Inc. IL purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $36,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research analyst reports. Stifel Nicolaus cut their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. JPMorgan Chase & Co. cut their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Piper Sandler cut their target price on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Finally, BTIG Research initiated coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price on the stock. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $574.13.

IDEXX Laboratories Trading Down 0.5 %

NASDAQ IDXX opened at $457.74 on Friday. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The company has a 50-day simple moving average of $487.50 and a 200-day simple moving average of $491.55. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. The firm has a market capitalization of $37.80 billion, a PE ratio of 44.31, a price-to-earnings-growth ratio of 4.14 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.01 billion. IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The firm’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the firm posted $2.67 earnings per share. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.